Septerna (SEPN) Preferred Stock Liabilities (2023 - 2024)
Septerna (SEPN) recorded quarterly Preferred Stock Liabilities of $149.5 million in Q3 2024, little changed quarter-over-quarter from $149.5 million in Q2 2024, and up 100.1% on a YoY basis from $74.7 million in Q4 2023.
Septerna (SEPN) Preferred Stock Liabilities (2023 - 2024) Analysis & Trends
Septerna's Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $149.5 million for Q3 2024.
- In Q3 2024, Preferred Stock Liabilities rose 100.1% year-over-year to $149.5 million; the TTM figure through Sep 2024 stood at $149.5 million (up 100.1% YoY), while the FY2023 annual figure was $74.7 million, changed N/A from the prior year.
- Preferred Stock Liabilities was $149.5 million for Q3 2024 at Septerna, roughly flat from $149.5 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $149.5 million in Q2 2024 to a low of $74.7 million in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Septerna | 1.62 Bn | 1.62 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 149.46 Mn |
| Jun 30, 2024 | 149.46 Mn |
| Mar 31, 2024 | 74.69 Mn |
| Dec 31, 2023 | 74.69 Mn |
| Sep 30, 2023 | 74.69 Mn |